Deutsche Bank AG Raises Stock Position in Prothena Co. plc (NASDAQ:PRTA)

Deutsche Bank AG increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 195.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 95,970 shares of the biotechnology company's stock after purchasing an additional 63,512 shares during the period. Deutsche Bank AG owned 0.18% of Prothena worth $1,329,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PRTA. SG Americas Securities LLC boosted its stake in shares of Prothena by 167.0% during the fourth quarter. SG Americas Securities LLC now owns 37,612 shares of the biotechnology company's stock valued at $521,000 after purchasing an additional 23,525 shares in the last quarter. Duncan Williams Asset Management LLC boosted its stake in shares of Prothena by 41.9% during the fourth quarter. Duncan Williams Asset Management LLC now owns 69,199 shares of the biotechnology company's stock valued at $958,000 after purchasing an additional 20,450 shares in the last quarter. Chicago Partners Investment Group LLC bought a new position in shares of Prothena during the fourth quarter valued at approximately $159,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Prothena by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 1,065 shares in the last quarter. Finally, Focused Wealth Management Inc acquired a new stake in Prothena in the fourth quarter valued at approximately $445,000. 97.08% of the stock is currently owned by institutional investors.

Prothena Trading Up 6.1%

Shares of NASDAQ PRTA traded up $0.28 during midday trading on Thursday, reaching $4.88. The company had a trading volume of 2,293,305 shares, compared to its average volume of 890,591. The business's 50-day simple moving average is $9.21 and its 200 day simple moving average is $12.66. The stock has a market cap of $262.68 million, a P/E ratio of -2.12 and a beta of 0.11. Prothena Co. plc has a 1 year low of $4.32 and a 1 year high of $25.42.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20). The company had revenue of $2.83 million during the quarter, compared to analysts' expectations of $8.18 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The company's quarterly revenue was up 5500.0% on a year-over-year basis. During the same period in the prior year, the business posted ($1.34) EPS. Analysts predict that Prothena Co. plc will post -4.04 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on PRTA shares. Cantor Fitzgerald downgraded shares of Prothena from an "overweight" rating to a "neutral" rating in a research note on Tuesday. Piper Sandler lowered their target price on shares of Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research note on Tuesday. HC Wainwright lowered their target price on shares of Prothena from $30.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday. Wall Street Zen upgraded shares of Prothena from a "sell" rating to a "hold" rating in a research note on Monday, February 24th. Finally, JMP Securities lowered their target price on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating for the company in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $31.50.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.